A Long-term Follow-up Study in Patients Previously Treated With Mustang Bio, Inc. CAR-T Cell Investigational Products
Latest Information Update: 25 Jul 2024
At a glance
- Drugs MB 102 Mustang Bio (Primary) ; MB-106 (Primary)
- Indications B-cell lymphoma; Blastic plasmacytoid dendritic cell neoplasm; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Hairy cell leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- Sponsors Mustang Bio
Most Recent Events
- 22 Jul 2024 Status changed from recruiting to discontinued for business reasons.
- 13 Dec 2022 New trial record